Structural Insights into Characterizing Binding Sites in Epidermal Growth Factor Receptor Kinase Mutants
Reads0
Chats0
TLDR
A comprehensive study of different EGFR kinase mutants using a structural systems pharmacology strategy shows that both wild-type and mutated structures exhibit multiple conformational states that have not been observed in solved crystal structures, providing insights for designing a new generation of EGFR Kinase inhibitor that combats acquired drug-resistant mutations through a multiconformation-based drug design strategy.Abstract:
Over the last two decades epidermal growth factor receptor (EGFR) kinase has become an important target to treat nonsmall cell lung cancer (NSCLC). Currently, three generations of EGFR kinase-targeted small molecule drugs have been FDA approved. They nominally produce a response at the start of treatment and lead to a substantial survival benefit for patients. However, long-term treatment results in acquired drug resistance and further vulnerability to NSCLC. Therefore, novel EGFR kinase inhibitors that specially overcome acquired mutations are urgently needed. To this end, we carried out a comprehensive study of different EGFR kinase mutants using a structural systems pharmacology strategy. Our analysis shows that both wild-type and mutated structures exhibit multiple conformational states that have not been observed in solved crystal structures. We show that this conformational flexibility accommodates diverse types of ligands with multiple types of binding modes. These results provide insights for designing a new generation of EGFR kinase inhibitor that combats acquired drug-resistant mutations through a multiconformation-based drug design strategy.read more
Citations
More filters
Journal ArticleDOI
Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism
TL;DR: In this article, the authors focused on EGFR small-molecule inhibitors that have been approved for clinical uses in cancer therapy and classified them based on their chemical structures, target kinases, and pharmacological uses.
Journal ArticleDOI
Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors
TL;DR: The structure of the extracellular, transmembrane, and intracellular domains of EGFR was described along with identifying the binding pose of commercially available inhibitors in the ATP-binding and allosteric sites, thereby clarifying the research gaps that can be filled and aiding the structure-based development of new drugs.
Journal ArticleDOI
Structural Insights into the Binding Modes of Viral RNA-Dependent RNA Polymerases Using a Function-Site Interaction Fingerprint Method for RNA Virus Drug Discovery.
Zheng Zhao,Philip E. Bourne +1 more
TL;DR: Structural binding-site insights for facilitating COVID-19 drug design when targeting RNA-dependent RNA polymerase (RDRP), a common conserved component of RNA viruses, are described and insights into the specific binding mechanisms important for containing the SARS-CoV-2 virus are provided.
Journal ArticleDOI
Harnessing systematic protein-ligand interaction fingerprints for drug discovery.
Zheng Zhao,Philip E. Bourne +1 more
TL;DR: In this article , the authors review recent progress and successful applications of a systematic protein-ligand interaction fingerprint (IFP) approach for investigating proteome-wide proteinligand interactions for drug development and demonstrate that the IFP strategy is efficient and practical for drug design research for protein kinases as targets.
Journal ArticleDOI
Antiproliferative activity, enzymatic inhibition and apoptosis-promoting effects of benzoxazole-based hybrids on human breast cancer cells.
TL;DR: New benzoxazole derivatives containing 1,3,4oxadiazole, 1,2,4-triazole or triazolothiadiazine rings were synthesized and screened for their in vitro antiproliferative activities against MCF-7 and MDA-MB-231 breast cancer cell lines using MTT assay.
References
More filters
Journal ArticleDOI
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
Vincent A. Miller,Vincent A. Miller,Vera Hirsh,Jacques Cadranel,Yuh Min Chen,Keunchil Park,Sang We Kim,Caicun Zhou,Wu Chou Su,M. Wang,Yan Sun,Dae Seog Heo,Lucio Crinò,Eng Huat Tan,Tsu Yi Chao,Mehdi Shahidi,X.J. Cong,Robert M. Lorence,James Chih-Hsin Yang +18 more
TL;DR: The findings for progression-free survival and response to treatment suggest that afatinib could be of some benefit to patients with advanced lung adenocarcinoma who have failed at least 12 weeks of previous EGFR tyrosine-kinase inhibitor treatment.
Journal ArticleDOI
MMTSB Tool Set: enhanced sampling and multiscale modeling methods for applications in structural biology
TL;DR: The design and implementation of the MMTSB Tool Set is described and its utility is illustrated with three typical examples--scoring of a set of predicted protein conformations in order to identify the most native-like structures, ab initio folding of peptides in implicit solvent with the replica exchange method, and the prediction of a missing fragment in a larger protein structure.
Journal ArticleDOI
The quest to overcome resistance to EGFR-targeted therapies in cancer
TL;DR: A comprehensive review of resistance pathways to EGFR-targeted therapies in lung, colorectal and head and neck cancers is presented and therapeutic strategies that are designed to circumvent resistance are discussed.
Journal ArticleDOI
Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site.
Christopher Pargellis,Liang Tong,Liang Tong,L. Churchill,Pier F. Cirillo,Gilmore Thomas A,A. G. Graham,Peter M. Grob,Eugene R. Hickey,Neil Moss,Susan Pav,John R. Regan +11 more
TL;DR: A new allosteric binding site for a diaryl urea class of highly potent and selective inhibitors against human p38 MAP kinase is reported, requiring a large conformational change not observed previously for any of the protein Ser/Thr kinases.
Journal ArticleDOI
ACEMD: Accelerating Biomolecular Dynamics in the Microsecond Time Scale.
TL;DR: This work provides a validation and performance evaluation of the code and runs a microsecond-long trajectory for an all-atom molecular system in explicit TIP3P water on a single workstation computer equipped with just 3 GPUs, believing that microsecond time scale molecular dynamics on cost-effective hardware will have important methodological and scientific implications.
Related Papers (5)
Mechanistic Insights into R776H Mediated Activation of Epidermal Growth Factor Receptor Kinase.
Zheng Ruan,Natarajan Kannan +1 more